




Ophthalmic
Therapeutic
Innovation

Setting New Standards of IOP Normalization for Glaucoma

Dr. Tina Guanting Qiu, MD, PhD, EMBA, CEO

May 2026



Trabodenoson is an adenosine mimetic optimized
to selectively target the A₁ receptor



Formula: C₁₅H₂₀N₆O₆ MW: 380.36


Problem: Rate Limiting Root Cause in Glaucoma: Outflow Engine Broken

118 million **glaucoma** patients by 2040 & 30% of those legally blind.




TM = Trabecular Meshwork. IOP: Intraocular Pressure

OTI's Solution and Competitive Landscape




Phase 2 Data: MMP Therapy on IOP Normalization & hVF Stability

Phase 2: OTI-2024 Treats Poor-Responder, is more effective in patients with POAG than OH in Lantanoprost poor responders.



OTI-2024 upregulated **MMP-14**, subsequently degraded fibronectin and collagen IV in cultural hTM cells.




B/C image from G. Li et al: IOVS, 2018 at the courtesy by Prof. Daniel Stamer.

Figure A from Inotek Pharma IPOS-1 form 2014..

Phase 3: Durysta derived MMP Therapy led to IOP Normalization (without random spike) at Week 8.


Phase 3: Durysta/MMP on IOP normalize at week 8.



Ref: Weinreb RN, et al. Ophthalmol Glaucoma. 2023 Nov-Dec;6(6):599-608.

Phase 3: Durysta is 12x more effective than Timolol in slowing down the VF loss in glaucoma.


Phase 3: Durysta/MMP on Neural Protection in Glaucoma at 12 months.



Ref: Bacharach, J. et al. ARTEMIS 2. *Drugs* **81**, 2017–2033 (2021).
Image courtesy by J Barcharach.

VF stability: Durysta
12x more effective than Timolol
5x more effective than istent.

Strategic Partnering/Licensing & Exit Strategy



- Exit via M&A or strategic licensing. Target valuation: \$600M-\$1B post-Phase 3 initiation. Comps: Aerie (\$770M), Eyebio (\$1.3B).